Home » Stocks » U.S. Stem Cell

U.S. Stem Cell, Inc. (USRM)

Stock Price: $0.0060 USD -0.0020 (-25.00%)
Updated Oct 22, 2020 2:16 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.44M
Revenue (ttm) 4.43M
Net Income (ttm) -3.60M
Shares Out 407.11M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $0.0060
Previous Close $0.0080
Change ($) -0.0020
Change (%) -25.00%
Day's Open 0.0080
Day's Range 0.0056 - 0.0080
Day's Volume 962,997
52-Week Range 0.003 - 0.017

More Stats

Market Cap 2.44M
Enterprise Value 8.63M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 407.11M
Float 369.66M
EPS (basic) -0.01
EPS (diluted) -0.01
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.63
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.55
PB Ratio n/a
Revenue 4.43M
Operating Income -2.58M
Net Income -3.60M
Free Cash Flow -965,914
Net Cash -6.19M
Net Cash / Share -0.02
Gross Margin 103.69%
Operating Margin -58.22%
Profit Margin -81.40%
FCF Margin -21.82%
ROA -95.37%
ROE n/a
ROIC 183.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201820172016201520142013
Revenue6.705.523.082.192.06-
Revenue Growth21.38%79.05%40.71%6.58%--
Gross Profit4.593.642.111.221.21-
Operating Income-1.10-0.80-1.16-2.61-3.53-
Net Income-2.16-3.48-2.07-1.64-2.25-
Shares Outstanding36630924.150.910.49-
Earnings Per Share-0.01-0.01-0.09-1.80-4.61-
Operating Cash Flow0.601.230.11-0.84-1.11-1.91
Capital Expenditures-0.40-0.01--0.01-0.01
Free Cash Flow0.601.630.10-0.85-1.12-1.92
Cash & Equivalents1.371.000.280.070.05-
Total Debt5.245.485.264.655.41-
Net Cash / Debt-3.87-4.48-4.98-4.58-5.37-
Assets1.821.600.430.230.20-
Liabilities8.708.708.457.9511.10-
Book Value-6.88-7.10-8.02-7.72-10.89-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name U.S. Stem Cell, Inc.
Country United States
Employees 10
CEO Miguel Tomás

Stock Information

Ticker Symbol USRM
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: USRM
IPO Date February 15, 2008

Description

U.S. Stem Cell, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.